Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $17.80

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) gapped up before the market opened on Wednesday . The stock had previously closed at $17.80, but opened at $18.43. Calliditas Therapeutics AB (publ) shares last traded at $18.36, with a volume of 1,530 shares changing hands.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, February 22nd.

Calliditas Therapeutics AB (publ) Stock Down 5.8 %

The company has a 50-day simple moving average of $21.13 and a 200 day simple moving average of $20.57. The company has a market cap of $525.79 million, a P/E ratio of -10.76 and a beta of 1.50. The company has a current ratio of 3.13, a quick ratio of 3.08 and a debt-to-equity ratio of 2.89.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last announced its quarterly earnings data on Wednesday, February 21st. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.02. The company had revenue of $42.45 million for the quarter, compared to the consensus estimate of $36.24 million. Calliditas Therapeutics AB (publ) had a negative return on equity of 104.47% and a negative net margin of 38.72%. During the same quarter in the prior year, the company posted ($0.01) EPS. On average, equities analysts anticipate that Calliditas Therapeutics AB will post 0.29 EPS for the current year.

Hedge Funds Weigh In On Calliditas Therapeutics AB (publ)

Hedge funds have recently bought and sold shares of the business. Optiver Holding B.V. purchased a new stake in shares of Calliditas Therapeutics AB (publ) in the 4th quarter worth $25,000. Tower Research Capital LLC TRC lifted its holdings in shares of Calliditas Therapeutics AB (publ) by 1,270.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,357 shares of the company’s stock worth $51,000 after buying an additional 3,112 shares during the period. Jane Street Group LLC lifted its holdings in shares of Calliditas Therapeutics AB (publ) by 7.6% in the 3rd quarter. Jane Street Group LLC now owns 12,491 shares of the company’s stock worth $191,000 after buying an additional 886 shares during the period. Finally, Deutsche Bank AG lifted its holdings in shares of Calliditas Therapeutics AB (publ) by 26.5% in the 1st quarter. Deutsche Bank AG now owns 90,509 shares of the company’s stock worth $2,170,000 after buying an additional 18,978 shares during the period. Institutional investors own 2.83% of the company’s stock.

Calliditas Therapeutics AB (publ) Company Profile

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.